Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial
ConclusionsMedian progression-free survival was numerically longer in Japanese patients in the veliparib-throughout versus control arm, consistent with results in the overall study population. Pharmacokinetics were comparable between Japanese and non-Japanese patients. Data for the subgroup of Japanese patients were not powered to show statistical significance but to guide further investigation.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Japan Health | Ovarian Cancer | Ovaries | Serous Carcinoma | Statistics | Study | Thrombocytopenia | Women | Zyprexa